Novartis AG (0QLR.IL)
| Previous Close | 92.22 |
| Open | 92.98 |
| Bid | 90.81 x N/A |
| Ask | 95.46 x N/A |
| Day's Range | 92.76 - 93.69 |
| 52 Week Range | 73.79 - 93.98 |
| Volume | |
| Avg. Volume | 603,880 |
| Market Cap | 191.893B |
| Beta (5Y Monthly) | 0.46 |
| PE Ratio (TTM) | 28.90 |
| EPS (TTM) | 3.21 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.20 (3.47%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | N/A |
GlobeNewswireSandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from extensive analytical characterization demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies. Sandoz is committed to accelerate access to potentially life-changing treatments, while generating savings for healthcare systems and patients aro
ZacksNovartis (NVS) Lutathera Meets Primary Goal in Phase III Study
Novartis' (NVS) radioligand therapy Lutathera reports statistically significant and clinically meaningful progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors study.
ZacksMerck (MRK), Eisai Combo Therapy Fail Two Lung Cancer Studies
Data from both late-stage studies evaluating Merck's (MRK) Keytruda and Eisai's Lenvima combination in certain types of metastatic non-small cell lung cancer, fail to achieve their primary endpoints.
